He spent a quarter century deciding which drugs were worth betting on. Then he started making one.
Most people pick a side. You either move money around the biotech industry, or you stand inside a company and try to turn a molecule into a medicine. Alexander Casdin did the first for twenty-five years - covering pharma stocks, running healthcare funds, sitting on boards - and then walked across the line to do the second. Today he is the Chief Executive Officer of Epirium Bio, and the drug he is responsible for is no longer a line in a portfolio. It is in human beings.
The neat version of a biotech career runs one direction: scientist, then operator, then maybe an investor at the end, once the lab coat gets old. Casdin ran it backwards. He started where the money sits and kept stepping toward where the science happens, one job at a time, until there was nowhere left to step except the chief executive's office.
His first serious seat was at the Dreyfus Corporation, where he was a senior managing analyst covering pharmaceuticals, biotechnology and medical devices. That is the job of judgment - reading data, reading management, deciding what is real. From there he ran healthcare money: portfolio manager at Pequot Capital Management's healthcare fund, then chief executive and portfolio manager at Cooper Hill Partners, then founder of his own shop, Casdin Advisors. Later he built and led Reneo Capital Management, a healthcare investment fund, as its founder, CEO and portfolio manager.
Somewhere in there the distance started to close. He took the CFO chair at Sophiris Bio. He ran finance as Vice President at Amylin Pharmaceuticals, a company that knew something about turning biology into product. The investor was becoming an operator, and the difference matters: an investor can be wrong and move on to the next position, while an operator has to be right, on the clock, with a team watching.
The board work runs alongside all of it, and it tells you something about how he is trusted. He joined the board of Erasca in 2018 and took the Audit Committee chair - the seat reserved for the person who is supposed to ask the uncomfortable financial questions before anyone else does. He has sat on the boards of Ignyta and Dusa Pharmaceuticals, both later acquired, and on the board of Sientra. These are not honorary chairs. They are the rooms where the hard calls about cash, dilution and survival get made, and Casdin keeps being asked into them.
In October 2020, Epirium Bio appointed Casdin its Chief Financial Officer. He did not stay in one box. He moved to Chief Operating Officer, the job where strategy meets the calendar, and then, on the first day of 2025, he became Chief Executive Officer. Russell Cox, the outgoing CEO, stepped up to Executive Chairman and described the moment plainly: a company moving from preclinical work into the clinic, handing the wheel to the person who had been steering the development.
The timing was not an accident of the calendar. The same stretch that produced Casdin's promotion also produced the milestone every biotech is built around: the FDA cleared Epirium's lead candidate, MF-300, to begin testing in people. A new title and a first human trial arrived together. For a man who had spent decades evaluating exactly this kind of inflection point from the outside, it landed differently from the inside.
"I am excited to accept the role of CEO during such a thrilling period for our company. I anticipate leading Epirium as we advance into clinical trials."
An investor can be wrong and move on. An operator has to be right, on the clock.
Epirium Bio works on small-molecule therapies designed to improve how muscle functions. Its lead drug, MF-300, is described as a first-in-class, orally dosed inhibitor of an enzyme called 15-PGDH. The condition in its sights is sarcopenia - the loss of muscle strength and mass that comes with age and erodes the simple business of standing, walking and staying independent.
The first study is the careful kind: a randomized, double-blinded, placebo-controlled dose-escalation trial in healthy participants, built to read safety, tolerability and how the body handles the drug, and to point toward the right dose for what comes next. It is the unglamorous, decisive first rung of clinical development - the part where promise either survives contact with reality or does not.
A rough read of each role by how close it sits to the science itself - from pure market judgment to running the company that makes the drug.
Director since 2018 and Chair of the Audit Committee at the precision-oncology company.
Former board member of Ignyta (bought by Roche) and Dusa Pharmaceuticals (bought by Sun Pharma).
Appointed to the board of directors in 2023.
Brown University Advisory Council on Biology and Medicine; Treasurer of ASCO's Conquer Cancer Foundation.
B.A. in Political Science. Not a science degree - a reminder that judgment travels.
Columbia Business School, elected to Beta Gamma Sigma.
Plenty of executives can read a balance sheet. Plenty of scientists can read a dose-response curve. The people who can do both, and who have spent decades watching how biotech bets actually pay off or fall apart, are scarce. Casdin's edge is not that he knows the molecule better than his chemists - it is that he has seen, from the investor's chair, what separates the companies that make it from the ones that do not.
There is a small irony worth noting. The Casdin name carries weight in biotech investing - Eli Casdin built the well-known firm Casdin Capital. Alexander Casdin's own advisory shop, Casdin Advisors, sits in the same alphabetical neighborhood. But his path is its own: not a famous fund, but a slow, deliberate walk from analyzing other people's drugs to being accountable for one of his own.
He took the top job at the exact moment the work got real. A preclinical company can run on conviction and slide decks. A clinical-stage company runs on data it cannot control, generated in bodies it does not own. That is the company Casdin chose to lead - the harder one, at the harder moment.
Consider the resume from the angle of what it cost. Each move toward the science meant giving up the comfort of the investor's distance. An analyst at Dreyfus is graded on the quality of an opinion. A portfolio manager is graded on returns across a book of many bets, where one failure is survivable. A CFO answers for the cash. A COO answers for the calendar. A CEO answers for everything, including the things no one can fully control - a trial readout, a regulator's mood, a competitor's surprise. Casdin spent his career trading away optionality for accountability, which is the opposite of what most successful investors do when they get the chance to stop.
The throughline is muscle and metabolism. Amylin built its reputation in metabolic disease. Epirium is building therapies to keep muscle working when age or disease tells it to stop. Even his board seats cluster in oncology and specialty medicine, the harder corners of drug development where the biology fights back. He is not a generalist who landed in biotech. He is someone who has spent an entire working life inside the same difficult neighborhood of human health, learning it from every seat the industry offers.
What he does next is the only question that matters now, and it is genuinely open. MF-300 has to clear Phase 1, then earn its way into the larger trials that decide whether sarcopenia gets a real drug or another disappointment. Casdin cannot will the data into existence. He can only build the company that gives the molecule its fairest shot - the right people, the right cash, the right decisions at the right moments. After twenty-five years of judging whether other people did that well, he finally has to do it himself.
Sources: Epirium Bio, BusinessWire, Bloomberg, Crunchbase, BioCentury, Sientra investor relations. Facts drawn from public records as of June 2026.